ÉlpisÉremo has unveiled a revolutionary Biosignature Recognition Technology named OculiDeus™, propelling fertility treatment to new heights and bringing us closer to the ultimate goal of enhanced fertility.

ELPISEREMO, an innovative bioengineering firm specializing in regenerative medicine, has introduced a groundbreaking noninvasive Biosignature Recognition Technology called OculiDeus™. This technology swiftly identifies and selects high-quality viable eggs (oocytes) during infertility treatment, offering a significant enhancement in prediction accuracy. The development of OculiDeus™ is expected to substantially improve pregnancy success rates in assisted reproductive technology (ART).

Infertility treatment often faces the challenge of age-related decline in ovarian function, impacting the quality of eggs. High-quality eggs are crucial for successful pregnancy, and OculiDeus™ addresses this critical aspect of fertility treatment. This technology facilitates the rapid identification and selection of viable eggs, providing a game-changing solution for couples struggling with infertility.

According to Oleg Verlinsky, CEO of Chicago’s RGI (Reproductive Genetic Innovations), age-related factors play a significant role in egg quality, with a decline in both quantity and quality over time. This underscores the importance of effective egg selection, as emphasized by Nobel Prize winner Dr. Robert Edwards.

James Ryan, CEO of ELPISEREMO and Executive Director of RGI-EAST, highlights the personal journey behind the development of OculiDeus™. He shares his own struggles with pregnancy loss and infertility, driving his commitment to revolutionizing infertility treatment. OculiDeus™ aims to address the challenges faced by couples undergoing infertility treatment, offering hope and tangible solutions.

OculiDeus™ leverages advanced hyperspectral camera vision technology, complemented by a proprietary Biological Artifactual Intelligence Model (BAiM). This combination enables high-resolution imaging and precise analysis of human cells, eggs, tissues, and organs. The integration of artificial intelligence further enhances diagnostic accuracy and prediction capabilities.

Prof. Carlo Ventura, CSO of ELPISEREMO, explains how OculiDeus™ facilitates real-time prediction of successful fertilization outcomes, guiding the selection of eggs suitable for cryopreservation. This personalized approach optimizes the pre-ICSI cryopreservation process, minimizing invasiveness and maximizing the chances of successful pregnancy.

The collaboration between ELPISEREMO and Reproductive Genetic Innovations East (RGI EAST) marks a significant step forward in assisted reproductive technology. OculiDeus™ has the potential to revolutionize fertility treatment, offering hope to countless couples worldwide.

ELPISEREMO’s transdisciplinary team is dedicated to advancing in vitro fertilization and human reproduction, addressing the complex challenges of infertility with innovative solutions.

For more information about ELPISEREMO and OculiDeus™, please visit their website. Contact James Ryan, CEO, for inquiries and further details.

Reproductive Genetic Innovations (RGI) is a global leader in assisted reproductive technologies, specializing in preimplantation genetic testing (PGT). Visit their website for more information.